The global antParkinson drugs market is expected to grow at a CAGR of 4.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of Parkinson's disease and growing geriatric population. The market is also driven by factors such as increasing number of clinical trials for new drugs and rising awareness about the disease among patients.
Dopaminergic drugs are expected to dominate the global antParkinson drugs market during the forecast period, due to their ability to increase dopamine levels in brain cells and reduce symptoms associated with Parkinson's disease. Dopamine agonists are expected to be the fastest-growing segment in this category, due to their ability to stimulate dopamine receptors in brain cells and reduce symptoms associated with Parkinson's disease. Enzyme inhibitors are also expected grow at a significant rate during the forecast period, due their ability inhibit enzymes that break down dopamine in brain cells and reduce symptoms associated with Parkinson's disease.
Some Of The Growth Factors Of This Market:
- Rising geriatric population base in developing countries such as China and India is also expected to fuel the demand for Anti-Parkinson Drugs over the forecast period.
- Increasing awareness about Parkinson's disease among people will also drive the growth of this market over the next few years as it helps in early diagnosis and treatment initiation which can help reduce symptoms and improve quality of life for patients with Parkinson's disease or other neurological disorders such as Alzheimer's disease, Huntington’s Disease, Tourette Syndrome etc, which are often associated with cognitive impairment or dementia symptoms that can be treated with Anti-Parkinson Drugs therapy.
Industry Growth Insights published a new data on “Anti-Parkinson Drugs Market”. The research report is titled “Anti-Parkinson Drugs Market research by Types (Dopaminergic, Dopamine Agonists, Enzyme Inhibitors, Others, Anti-Parkinson Drug), By Applications (Hospital Pharmacy, Retail Pharmacy, Online Stores), By Players/Companies AbbVie, Mylan Laboratories, Valeant Pharmaceuticals, Novartis, GlaxoSmithKline, Zambon Pharmaceuticals, Pfizer, Inc., Hoffmann-La Roche, Merck & Co., Orion Pharma, UCB, Teva Pharmaceutical Industries Ltd., Vertical Pharmaceuticals, LLC, ACADIA Pharmaceuticals Inc., Anti-Parkinson Drug”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Anti-Parkinson Drugs Market Research Report
By Type
Dopaminergic, Dopamine Agonists, Enzyme Inhibitors, Others, Anti-Parkinson Drug
By Application
Hospital Pharmacy, Retail Pharmacy, Online Stores
By Companies
AbbVie, Mylan Laboratories, Valeant Pharmaceuticals, Novartis, GlaxoSmithKline, Zambon Pharmaceuticals, Pfizer, Inc., Hoffmann-La Roche, Merck & Co., Orion Pharma, UCB, Teva Pharmaceutical Industries Ltd., Vertical Pharmaceuticals, LLC, ACADIA Pharmaceuticals Inc., Anti-Parkinson Drug
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Anti-Parkinson Drugs Market Report Segments:
The global Anti-Parkinson Drugs market is segmented on the basis of:
Types
Dopaminergic, Dopamine Agonists, Enzyme Inhibitors, Others, Anti-Parkinson Drug
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Retail Pharmacy, Online Stores
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Mylan Laboratories
- Valeant Pharmaceuticals
- Novartis
- GlaxoSmithKline
- Zambon Pharmaceuticals
- Pfizer, Inc.
- Hoffmann-La Roche
- Merck & Co.
- Orion Pharma
- UCB
- Teva Pharmaceutical Industries Ltd.
- Vertical Pharmaceuticals, LLC
- ACADIA Pharmaceuticals Inc.
- Anti-Parkinson Drug
Highlights of The Anti-Parkinson Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Dopaminergic
- Dopamine Agonists
- Enzyme Inhibitors
- Others
- Anti-Parkinson Drug
- By Application:
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti-Parkinson Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Some of the key players operating in the anti-parkinson drugs market are AbbVie, Mylan Laboratories, Valeant Pharmaceuticals, Novartis, GlaxoSmithKline, Zambon Pharmaceuticals, Pfizer, Inc., Hoffmann-La Roche, Merck & Co., Orion Pharma, UCB, Teva Pharmaceutical Industries Ltd., Vertical Pharmaceuticals, LLC, ACADIA Pharmaceuticals Inc., Anti-Parkinson Drug.
The anti-parkinson drugs market is expected to grow at a compound annual growth rate of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Anti-Parkinson Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Anti-Parkinson Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Anti-Parkinson Drugs Market - Supply Chain
4.5. Global Anti-Parkinson Drugs Market Forecast
4.5.1. Anti-Parkinson Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Anti-Parkinson Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Anti-Parkinson Drugs Market Absolute $ Opportunity
5. Global Anti-Parkinson Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Anti-Parkinson Drugs Market Size and Volume Forecast by Type
5.3.1. Dopaminergic
5.3.2. Dopamine Agonists
5.3.3. Enzyme Inhibitors
5.3.4. Others
5.3.5. Anti-Parkinson Drug
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Anti-Parkinson Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Anti-Parkinson Drugs Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacy
6.3.2. Retail Pharmacy
6.3.3. Online Stores
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Anti-Parkinson Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Anti-Parkinson Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Anti-Parkinson Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Anti-Parkinson Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Anti-Parkinson Drugs Demand Share Forecast, 2019-2026
9. North America Anti-Parkinson Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Anti-Parkinson Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Anti-Parkinson Drugs Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacy
9.4.2. Retail Pharmacy
9.4.3. Online Stores
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Anti-Parkinson Drugs Market Size and Volume Forecast by Type
9.7.1. Dopaminergic
9.7.2. Dopamine Agonists
9.7.3. Enzyme Inhibitors
9.7.4. Others
9.7.5. Anti-Parkinson Drug
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Anti-Parkinson Drugs Demand Share Forecast, 2019-2026
10. Latin America Anti-Parkinson Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Anti-Parkinson Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Anti-Parkinson Drugs Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacy
10.4.2. Retail Pharmacy
10.4.3. Online Stores
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Anti-Parkinson Drugs Market Size and Volume Forecast by Type
10.7.1. Dopaminergic
10.7.2. Dopamine Agonists
10.7.3. Enzyme Inhibitors
10.7.4. Others
10.7.5. Anti-Parkinson Drug
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Anti-Parkinson Drugs Demand Share Forecast, 2019-2026
11. Europe Anti-Parkinson Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Anti-Parkinson Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Anti-Parkinson Drugs Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacy
11.4.2. Retail Pharmacy
11.4.3. Online Stores
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Anti-Parkinson Drugs Market Size and Volume Forecast by Type
11.7.1. Dopaminergic
11.7.2. Dopamine Agonists
11.7.3. Enzyme Inhibitors
11.7.4. Others
11.7.5. Anti-Parkinson Drug
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Anti-Parkinson Drugs Demand Share, 2019-2026
12. Asia Pacific Anti-Parkinson Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Anti-Parkinson Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Anti-Parkinson Drugs Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacy
12.4.2. Retail Pharmacy
12.4.3. Online Stores
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Anti-Parkinson Drugs Market Size and Volume Forecast by Type
12.7.1. Dopaminergic
12.7.2. Dopamine Agonists
12.7.3. Enzyme Inhibitors
12.7.4. Others
12.7.5. Anti-Parkinson Drug
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Anti-Parkinson Drugs Demand Share, 2019-2026
13. Middle East & Africa Anti-Parkinson Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Anti-Parkinson Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Anti-Parkinson Drugs Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacy
13.4.2. Retail Pharmacy
13.4.3. Online Stores
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Anti-Parkinson Drugs Market Size and Volume Forecast by Type
13.7.1. Dopaminergic
13.7.2. Dopamine Agonists
13.7.3. Enzyme Inhibitors
13.7.4. Others
13.7.5. Anti-Parkinson Drug
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Anti-Parkinson Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Anti-Parkinson Drugs Market: Market Share Analysis
14.2. Anti-Parkinson Drugs Distributors and Customers
14.3. Anti-Parkinson Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AbbVie
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Mylan Laboratories
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Valeant Pharmaceuticals
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. GlaxoSmithKline
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Zambon Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Pfizer, Inc.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Hoffmann-La Roche
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Merck & Co.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Orion Pharma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. UCB
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Teva Pharmaceutical Industries Ltd.
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Vertical Pharmaceuticals, LLC
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. ACADIA Pharmaceuticals Inc.
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Anti-Parkinson Drug
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
